Cynthia B. Leary

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu et al. · Cancer Cell · 2019 · 277 citations

Medicine, Oncology, Pharmacology +17

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors

Allison S. Harney, George S. Karagiannis, Jeanine Pignatelli et al. · Molecular Cancer Therapeutics · 2017 · 169 citations · Full text

Medicine, Oncology, Pharmacology +17

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

Bryan D. Smith, Michael D. Kaufman, Cynthia B. Leary et al. · Molecular Cancer Therapeutics · 2015 · 77 citations

Medicine, Oncology, Pharmacology +17

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages

Bryan D. Smith, Michael D. Kaufman, Scott Wise et al. · Molecular Cancer Therapeutics · 2021 · 71 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)

Timothy M. Caldwell, Yu Mi Ahn, Stacie L. Bulfer et al. · Bioorganic & Medicinal Chemistry Letters · 2022 · 39 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14